Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | GALR3 | O60755 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 12/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | FPR1 | P21462 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | MELK | Q14680 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL398550 | 1.00 | RAB9A (0.41) | RAB9AGALR3CCR3MEN1KMT2A | |
| SCHEMBL401209 | 0.95 | RAB9A (0.44) | RAB9AGALR3CCR3MEN1KMT2A | |
| SCHEMBL401102 | 0.94 | CCR3 (0.42) | RAB9AGALR3CCR3MEN1KMT2A | |
| SCHEMBL401771 | 0.94 | CCR3 (0.42) | RAB9AGALR3CCR3MEN1KMT2A | |
| SCHEMBL402784 | 0.92 | CCR3 (0.39) | RAB9AGALR3CCR3NPC1MAPT | |
| SCHEMBL400464 | 0.92 | CCR3 (0.39) | RAB9AGALR3CCR3NPC1MAPT | |
| SCHEMBL399149 | 0.92 | CCR3 (0.39) | RAB9AGALR3CCR3NPC1MAPT | |
| SCHEMBL398992 | 0.92 | JAK2 (0.43) | RAB9AGALR3CCR3NPC1MAPT | |
| SCHEMBL400960 | 0.92 | JAK2 (0.43) | RAB9AGALR3CCR3NPC1MAPT | |
| SCHEMBL4002497 | 0.92 | JAK2 (0.43) | RAB9AGALR3CCR3NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198203-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2021-07-01 | — | — | US | claimed |
| US-20190352267-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2019-11-21 | — | — | US | claimed |
| US-20180305316-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2018-10-25 | — | — | US | claimed |
| EP-2862859-A2 | Compounds, compositions and methods | Cytokinetics, Inc. (US) | 2015-04-22 | — | — | EP | claimed |
| US-20150005296-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2015-01-01 | — | — | US | claimed |
| US-8110595-B2 | Ureas and their use in the treatment of heart failure | CYTOKINETICS, INC. (US) | 2012-02-07 | — | — | US | claimed |
| EP-1765327-A4 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2009-06-17 | — | — | EP | claimed |
| US-20090036447-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. (US) | 2009-02-05 | — | — | US | claimed |
| EP-1765327-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2007-03-28 | — | — | EP | claimed |
| WO-2006009726-A2 | SUBSTITUTED UREA DERIVATIVES FOR TREATING CARDIAC DISEASES | CYTOKINETICS, INC. (US) | 2006-01-26 | — | — | WO | claimed |
| US-12264133-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2025-04-01 | — | — | US | disclosed |
| US-20220185779-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2022-06-16 | — | — | US | disclosed |
| US-20210198203-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2021-07-01 | — | — | US | disclosed |
| US-10975034-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190352267-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2019-11-21 | — | — | US | disclosed |
| US-20070197505-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070161617-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
| EP-1765327-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006009726-A2 | SUBSTITUTED UREA DERIVATIVES FOR TREATING CARDIAC DISEASES | CYTOKINETICS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20060014761-A1 | Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate | CYTOKINETICS, INCORPORATED | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161617-A1 | Certain chemical entities, compositions and methods | TNNI3, TNNT2, MYLK2 | RAB9A 3170/4885GALR3 4019/4885CCR3 4640/4885 |
| US-20060014761-A1 | Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate | TNNI3, MYLK2, TNNT2 | RAB9A 2091/4885GALR3 4620/4885CCR3 4670/4885 |
| US-20220185779-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | RAB9A 2773/4885GALR3 4008/4885CCR3 4522/4885 |
| US-12264133-B2 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | RAB9A 2773/4885GALR3 4008/4885CCR3 4522/4885 |
| US-20190352267-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | RAB9A 2773/4885GALR3 4008/4885CCR3 4522/4885 |
| US-20070197505-A1 | Certain chemical entities, compositions and methods | TNNC1, TNNI3, TNNT2 | RAB9A 3510/4885GALR3 1699/4885CCR3 3421/4885 |
| US-20150005296-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | RAB9A 2773/4885GALR3 4008/4885CCR3 4522/4885 |
| US-10975034-B2 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | RAB9A 2773/4885GALR3 4008/4885CCR3 4522/4885 |
| US-20090036447-A1 | Compounds, Compositions and Methods | TNNI3, TNNC1, TNNT2 | RAB9A 2773/4885GALR3 4008/4885CCR3 4522/4885 |
| US-20180305316-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | RAB9A 2773/4885GALR3 4008/4885CCR3 4522/4885 |
| US-20210198203-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | RAB9A 2773/4885GALR3 4008/4885CCR3 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.